Clinical trials: Apixaban
Short Bowel Syndrome, Anticoagulation
Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition
Short bowel syndrome (SBS) is defined as a loss of function of the small intestine resulting in a malabsorptive disorder. In SBS, oral drug absorption may be altered due to extensive intestinal resection.
- Trial name
- ABSORB (NCT04344717)
- Testing
- Apixaban single dose, Apixaban steady-state
- Where
- Belgium
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Atrial Fibrillation
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
The study goal is to determine the clinical benefit of percutaneous catheter-based left atrial appendage (LAA) closure in patients with non-valvular atrial fibrillation (NVAF) at high risk of stroke (CHA2DS2-VASc Score ≥2) as…
- Trial name
- CLOSURE-AF (NCT03463317)
- Testing
- CE-mark approved LAA closure devices, Acetylsalicylic acid, Clopidogrel
- Where
- 42 sites in Germany
- Volunteers
- 912 people
- Sponsor
- Charite University, Berlin, Germany
Venous Thromboembolism
Eliquis Regulatory Post Marketing Surveillance (rPMS)
The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the safety and effectiveness information about…
- Trial name
- NCT01885585
- Testing
- Apixaban
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation
The purpose of this study is to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of MAA868 compared to apixaban in patients with atrial fibrillation.
- Trial name
- NCT03398434
- Testing
- MAA868, Apixaban
- Sponsor
- Novartis Pharmaceuticals
Diabetes
ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)
Diabetic and nondiabetic patients will be evaluated if they had a first diagnosis of non-valvular atrial fibrillation and in therapy with non-vitamin K oral anticoagulants and with vitamin K oral anticoagulants.
- Trial name
- ORGANON (NCT02935855)
- Testing
- Dabigatran, Apixaban, Rivaroxaban
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Pavia
Venous Thromboembolism, Varicose Veins
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
Endovenous interventions are keyhole operations for varicose veins that are carried out from within the vein itself. Varicose veins are enlarged veins close to the surface of the skin.
- Trial name
- THRIVE (NCT05735639)
- Testing
- Dalteparin Sodium, Tinzaparin Sodium, Enoxaparin Sodium
- Where
- United Kingdom
- Volunteers
- 3,175 people
- Sponsor
- Imperial College London
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT)
Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease
People who have surgery on their spine to treat cancer that has spread (metastatic disease) have a high chance of developing dangerous blood clots in the legs or lungs.
- Conditions
- Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Spine Metastasis
- Trial name
- NCT07713875
- Testing
- Apixaban
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- James Bayley
Healthy Volunteers
Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects
The purpose of this study is to assess the oral bioavailability of Apixaban solution formulation (Treatment B, 10 mg as 25 mL x 0.4 mg/mL) relative to Apixaban tablets (Treatment A, 10 mg as 2 x 5 mg tablets) in healthy subjects.
- Trial name
- NCT02034565
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Thrombosis, Bleeding
Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.
The goal of this retrospective clinical trial is to find out association antiplatelet and anticoagulant therapy with perioperative complications in non-cardiac vascular surgery in patients .
- Conditions
- Thrombosis, Bleeding, Cerebral Hypoxia During and/or Resulting From A Procedure
- Trial name
- NCT07358416
- Testing
- Aspirin, Clopidogrel, Ticagrelor
- Where
- Russia
- Volunteers
- 500 people
- Sponsor
- Petrovsky National Research Centre of Surgery
Covid19
COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis
A multicenter, adaptive, randomized platform trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge
- Trial name
- NCT04650087
- Testing
- Apixaban 2.5 MG
- Where
- 121 sites in United States
- Volunteers
- 1,291 people
- Sponsor
- Thomas L. Ortel
Cirrhosis, Splenectomy
Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection
The purpose of this study is to determine whether Apixaban is effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients after Laparoscopic Splenectomy and Azygoportal Disconnection
- Conditions
- Cirrhosis, Splenectomy, Venous Thrombosis, Hypertension, Portal
- Trial name
- ESAPT (NCT05304455)
- Testing
- Apixaban 2.5 MG, Dipyridamole 25Mg Tab, subcutaneous Low Molecular Weight Heparin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Northern Jiangsu People's Hospital
Atrial Fibrillation Patients With Intermediate Stroke Risk
The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)
Atrial fibrillation (AF) increases the risk of stroke, and oral anticoagulation is strongly recommended for patients at high thromboembolic risk.
- Trial name
- NCT04437654
- Testing
- Anticoagulation group(DOAC group)
- Where
- South Korea
- Volunteers
- 1,803 people
- Sponsor
- Yonsei University
Heparin-induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis
Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)
This research study is studying a drug as a possible treatment for heparin induced thrombocytopenia (HIT) or Heparin-induced Thrombocytopenia and Thrombosis (HITT). The drug involved in this study is apixaban.
- Trial name
- NCT03594045
- Testing
- Apixaban
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Massachusetts General Hospital
Renal Disease, End Stage, Anticoagulant-induced Bleeding
Safety and Efficacy of Apixaban in Severe Renal Impairment
Despite emergence of new anticoagulants over the last few years, patients with advanced chronic kidney disease still have limited options and are usually managed with warfarin after venous thromboembolism or diagnosis of atrial…
- Trial name
- NCT03399305
- Where
- United States
- Sponsor
- Albert Einstein College of Medicine
Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation
Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
In this open-label, prospective, randomized pilot study, patients who develop atrial fibrillation after isolated coronary artery bypass grafting surgery will be identified.
- Conditions
- Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation, Stroke, Systemic Embolism
- Trial name
- NCT02889562
- Testing
- Apixaban, Warfarin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Sanford Health
Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB)
FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants)
Background Non-vitamin K antagonist oral anticoagulants (NOACs) are recommended for stroke prevention in non-valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB), Gastrointestinal Hemorrhage (Clinically Important, Upper), Drug-Related Side Effects and Adverse Reactions
- Trial name
- FENOX (NCT07497893)
- Testing
- Fexuprazan, NOAC therapy
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Ewha Womans University Mokdong Hospital
Uterine Hemorrhage
A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants
The purpose of this study is assess the: (a) incidence of severe uterine bleeding (SUB) following exposure to individual direct oral anticoagulant (DOACs) (rivaroxaban, apixaban, dabigatran) and warfarin, (b) individual DOACs…
- Trial name
- NCT04394234
- Testing
- Direct oral anticoagulant (DOACs), Warfarin
- Where
- United States
- Volunteers
- 961,985 people
- Sponsor
- Janssen Research & Development, LLC
Coagulation
Multi-site Study for Evaluation of Clinical Ranges of Whole Blood Clotting Times of Patients on Anticoagulants and Verification of Measurement Precision of Liquid Quality Controls With the Perosphere Technologies' PoC Coagulometer
The Perosphere Technologies' PoC Coagulometer measures clotting times of fresh whole blood samples. Clotting is initiated by glass surface activation and terminates on optical detection of fibrin assembly, the final step in the…
- Trial name
- NCT04868214
- Testing
- coagulation measurements
- Where
- 5 sites in United States, Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sciema UG
Heart Failure
Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices
Prospective, randomized, controlled, open label, trial of LVAD patients with 1:1 randomization to either apixaban or warfarin.
- Trial name
- DOAC LVAD (NCT04865978)
- Testing
- Apixaban, Warfarin, LVAD implant
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Palak Shah
Ischemic Stroke, TIA
Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events
Nondisabling cerebrovascular events represent the largest group of cerebrovascular disease with a high risk of recurrent stroke.
- Trial name
- ADANCE (NCT01924325)
- Testing
- Apixaban, Clopidogrel, Aspirin
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Xijing Hospital